Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227513 · ClinicalTrials.gov registry record · Phase 1
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00227513: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00227513 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00227513, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of vorinostat and bortezomib in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Interventions
- DRUG vorinostat
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2005-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227513
The ClinicalTrials.gov registry entry for NCT00227513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vorinostat is the first listed.
NCT00227513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227513 about?
NCT00227513 is a clinical study titled "Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors". This phase I trial is studying the side effects and best dose of vorinostat and bortezomib in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by st...
What is the current status of trial NCT00227513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00227513?
The interventions under investigation include: vorinostat (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00227513?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.